A IIT Study of 177Lu-DOTA-SNA040

This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced Claudin18.2-positive solid tumors (e.g., gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, cholangiocarcinoma, etc.) who have disease progression following first-line therapy.

Trial Details

NCT ID
NCT07595237
Phase
EARLY_PHASE1
Sponsor
SmartNuclide Biopharma
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • 177Lu-DOTA-SNA040
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age range of 18 to 75 years old (including boundary values);
  • Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
  • Individuals with ECOG scores ranging from 0 to 1 (see Appendix 1 for details);
  • Life expectancy\>6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →